-
1 week ago | 
ajmc.com | Laura Joszt |Hayden E. Klein |David Awad
Captions were auto-generated. As value-based care models expand across the oncology landscape, pharmacists play a growing role in navigating the complex intersection of therapeutic innovation, fiscal responsibility, and patient access. In an interview with The American Journal of Managed Care®(AJMC®),David Awad, PharmD, BCOP, oncology pharmacy manager at Robert Wood Johnson University Hospital, described the balancing act pharmacy teams must perform in the current treatment landscape.
-
1 week ago | 
ajmc.com | Hayden E. Klein |Merrill Stewart
Captions were auto-generated. Despite offering superior accuracy in detecting coronary artery disease (CAD), cardiac positron emission tomography (PET) stress testing has not yet become standard practice in most cardiology clinics in the US. According to Merrill H. Stewart, MD, director of nuclear cardiology and noninvasive and critical care cardiologist at Ochsner Health, the primary reason is not clinical hesitancy—it’s cost.
-
1 week ago | 
ajmc.com | Hayden E. Klein |Hamlet Gasoyan
Captions were auto-generated. In real-world practice, patients taking glucagon-like peptide-1 (GLP-1) receptor agonists as an obesity treatment experience less weight loss than those in clinical trials, according research from Cleveland Clinic.
-
1 week ago | 
ajmc.com | Mary Caffrey |Hayden E. Klein
Since 1980, the global prevalence of rheumatoid arthritis (RA) has risen sharply, with incidence growing 13.2% over 3 decades from 1990 to 2021, according to a study published today in Annals of the Rheumatic Diseases.1 In addition, there are significant regional disparities and a shifting age profile.
-
2 weeks ago | 
ajmc.com | Hayden E. Klein
As the global burden of metabolic disease continues to grow, the Global Liver Institute (GLI) marked Global Fatty Liver Day 2025 with an urgent call for action to address steatotic liver disease (SLD), now recognized as one of the most prevalent and underdiagnosed health threats of the 21st century according to a GLI news release.1 Observed annually on the second Thursday in June, Global Fatty Liver Day aims to raise awareness of the escalating public health crisis posed by fatty liver...
-
2 weeks ago | 
ajmc.com | Hayden E. Klein
Subcutaneous tocilizumab (Actemra; Genentech) used alone or in combination with methotrexate is significantly more effective than methotrexate monotherapy in treating moderate to severe rheumatoid arthritis (RA) among Chinese patients, according to findings from a large-scale randomized clinical trial published in JAMA Network Open.
-
2 weeks ago | 
ajmc.com | Laura Joszt |Hayden E. Klein |David Awad
David Awad, PharmD, BCOP, oncology pharmacy manager, Robert Wood Johnson University Hospital, emphasizes the importance of documentation and communication in supporting seamless collaboration between pharmacists and oncology providers. By tracking medication-related interventions and maintaining transparency across cycles of therapy, he says pharmacists can help ensure patients can safely continue beneficial treatments while avoiding unnecessary drug holds or changes.
-
2 weeks ago | 
ajmc.com | Laura Joszt |Hayden E. Klein |Mansi Shah
While chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies, and other novel therapies are transforming multiple myeloma treatment, stem cell transplant remains a cost-effective and widely accessible first-line option, according to Mansi Shah, MD, clinical director of multiple myeloma at Rutgers Cancer Institute.
-
2 weeks ago | 
ajmc.com | Hayden E. Klein
The FDA has approved clesrovimab-cfor (Enflonsia), Merck’s long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, the company announced.1 According to Merck, this approval offers providers a second passive immunization option for infants following the 2023 approval of nirsevimab (Beyfortus).2 The company expects ordering to begin in July 2025, with...
-
2 weeks ago | 
ajmc.com | Hayden E. Klein
In clinical practice, injectable glucagon-like peptide-1 (GLP-1) receptor agonists for obesity treatment appear less effective than in clinical trials, largely due to early discontinuation and low maintenance dosing, according to a study published in Obesity.1 Cleveland Clinic’s retrospective cohort study of 7881 adults with obesity found that while semaglutide and tirzepatide can support meaningful weight loss and improve glycemic control in patients with prediabetes, real-world outcomes...
